Digital endpoints have become one of the most important innovations in modern clinical research. With wearable sensors, connected devices, and remote monitoring technologies more widely adopted, sponsors are increasingly incorporating digital measures into clinical trials.
The goal is to capture objective, continuous insights into patient health and treatment response. Developing a digital endpoint, however, is far more complex than selecting a wearable device or collecting large volumes of data.
A successful digital endpoint must be scientifically valid, clinically meaningful, operationally feasible, and supported by evidence that satisfies regulatory expectations. Achieving these objectives requires expertise that spans multiple disciplines, making partner selection an important strategic decision for sponsors.
Many organizations claim to support digital measurement, but their capabilities often vary considerably. Some provide wearable devices, others specialize in data analytics, while only a select group possesses the scientific, clinical, and regulatory expertise needed.
This article explains who develops digital endpoints, why specialized expertise matters, and how sponsors can evaluate potential partners when selecting an organization to support digital endpoint development.
Understanding Digital Endpoints
Digital endpoints are clinical trial outcome measures that are derived from data collected through digital technologies. These can be wearable sensors, smartphones, connected medical devices, or remote monitoring platforms.
Unlike traditional endpoints that rely on intermittent clinical assessments, digital endpoints often incorporate continuous or high-frequency measurements. These are typically collected while participants go about their daily lives.
This approach provides sponsors with a more comprehensive understanding of disease progression, treatment response, and patient functioning. Digital endpoints may assess outcomes such as:
- Mobility and gait
- Physical activity
- Sleep quality
- Respiratory performance
- Cardiac function
- Cognitive performance
- Daily functioning
These measures can improve sensitivity, reduce subjectivity, and better reflect outcomes that are meaningful to patients.
However, a digital endpoint is much more than a measurement generated by a wearable device. It is a rigorously developed clinical outcome that must demonstrate scientific validity and clinical relevance within its intended context of use.
Who Develops Digital Endpoints?
Developing digital endpoints requires expertise that extends beyond traditional clinical trial operations. The development is typically a collaborative effort involving specialists from multiple disciplines. Depending on the complexity of the clinical program, development teams may include:
- Clinical scientists
- Physicians and therapeutic area experts
- Biostatisticians
- Data scientists
- Digital health specialists
- Wearable sensor experts
- Software engineers
- Regulatory specialists
- Clinical operations professionals
- Patient experience experts
Each discipline contributes unique expertise to ensure that a digital endpoint is scientifically sound, clinically meaningful, and operationally practical. Sponsors partner with organizations that specialize in digital measurement science, as these capabilities are rarely available within a single internal team.
Why Specialized Expertise Matters?
Many organizations can collect wearable sensor data. Far fewer can transform that data into validated digital endpoints capable of supporting regulatory decision-making. Developing digital endpoints requires expertise across every stage of the measurement lifecycle.
The process involves defining clinically meaningful concepts and selecting appropriate wearable technologies. The next step is to develop digital biomarkers and design validation strategies. These typically include establishing analytical validity and demonstrating clinical validity.
The aim is to support statistical analysis and prepare regulatory evidence. Without this multidisciplinary expertise, sponsors risk developing measurements that generate data but fail to provide meaningful clinical insights.
Specialized partners help ensure that digital endpoints are designed with scientific rigor from the earliest stages of study planning.
What Services Should a Digital Endpoint Partner Provide?
Not every organization offering wearable technology services provides comprehensive digital endpoint development support. Sponsors should evaluate whether a potential partner offers capabilities that extend throughout the entire development process, such as:
Digital Endpoint Strategy
A strong partner begins by understanding the scientific objectives of the study. Rather than recommending technologies immediately, experienced organizations help sponsors determine which clinical concepts should be measured and how digital endpoints can best support study objectives.
Wearable Sensor Evaluation
Selecting the appropriate technology is a critical component of endpoint development. An effective partner evaluates wearable sensors based on scientific evidence, measurement capabilities, participant usability, and operational feasibility rather than manufacturer specifications alone.
Digital Biomarker Development
Many digital endpoints are built using validated digital biomarkers. Specialized organizations help sponsors transform raw sensor data into objective measurements that accurately reflect patient health or functioning.
Validation Planning
Validation remains one of the most important aspects of digital endpoint development. An experienced partner should support analytical validation, clinical validation, reliability assessments, and evidence generation activities necessary to establish that a digital endpoint is fit for its intended use.
Data Analytics and Statistical Support
Digital endpoints generate large amounts of complex information. Experienced partners should provide advanced analytical capabilities, statistical expertise, quality monitoring, and interpretation strategies that maximize the scientific value of wearable-generated data.
Regulatory Support
Digital endpoint development should always consider future regulatory interactions. Specialized organizations can help sponsors prepare documentation, validation evidence, and scientific rationale that support discussions with regulatory agencies throughout clinical development.
How to Evaluate a Digital Endpoint Partner?
Choosing the right partner involves more than reviewing marketing materials or technology demonstrations. Sponsors should assess whether an organization possesses the scientific expertise, operational capabilities, and regulatory experience needed.
A suitable partner must be capable of supporting successful digital endpoint development. Below are the key aspects of such a partner.
Assess Scientific Expertise
Sponsors should evaluate whether potential partners demonstrate expertise in digital measurement science, wearable sensor validation, digital biomarker development, and clinical outcome assessment. Published research, peer-reviewed evidence, scientific presentations, and contributions to industry initiatives can all indicate the depth of an organization’s expertise.
Evaluate Validation Experience
Validation is central to successful digital endpoint development. Sponsors should ask potential partners about their experience with validation, both analytical and clinical. They must also understand the partner’s role in testing, evaluation, verification, and context of use development.
Organizations that can clearly explain their validation methodology are generally better positioned to support regulatory quality evidence generation.
Review Therapeutic Area Experience
Different therapeutic areas present unique measurement challenges. Neurological disorders, respiratory diseases, cardiovascular conditions, oncology, rare diseases, and musculoskeletal disorders all require different clinical expertise and endpoint strategies. Sponsors should evaluate whether a potential partner has experience supporting studies within their specific therapeutic area.
Examine Regulatory Knowledge
Successful digital endpoints must ultimately withstand regulatory review. Sponsors should determine whether potential partners understand evolving regulatory expectations and have experience supporting submissions involving digital measures. Early regulatory planning often improves development efficiency while reducing downstream risks.
Evaluate Operational Capabilities
Scientific expertise alone is not sufficient. Sponsors should also consider whether a partner can support device deployment, participant training, and site support. Other capabilities will include data monitoring and technical troubleshooting.
This ensures quality management and enables global study operations. These strong operational capabilities help ensure that digital endpoint strategies can be implemented consistently across complex clinical programs.
Consider Collaboration Style
Digital endpoint development requires close collaboration between sponsors and specialized partners. Organizations that function as strategic collaborators rather than technology vendors often provide greater long-term value. Open communication, scientific transparency, and multidisciplinary teamwork contribute significantly to successful endpoint development.
Questions Sponsors Should Ask Potential Partners
Evaluating a digital endpoint partner becomes easier when sponsors ask focused questions about scientific capabilities and implementation experience. Below is a list of useful questions that sponsors can ask when evaluating a potential partner:
- How do you define clinically meaningful digital endpoints?
- What experience do you have developing digital biomarkers?
- How do you approach analytical and clinical validation?
- Which wearable technologies have you evaluated?
- How do you support regulatory interactions?
- What therapeutic areas have you worked in?
- How do you manage data quality throughout a study?
- What statistical expertise supports endpoint development?
- How do you ensure participant usability and adherence?
- Can your team support global clinical trials?
The answers to these questions often reveal whether an organization truly specializes in digital endpoint development or primarily provides technology implementation services.
Common Mistakes When Selecting a Partner
Selecting a partner for digital endpoint development can significantly influence the success of a clinical trial. While many organizations offer digital health services, not all have the specialized expertise required to develop scientifically robust and regulatory-ready digital endpoints.
Understanding the following common mistakes can help sponsors identify partners that are better equipped to support successful digital endpoint development.
Prioritizing Technology Over Science
A common mistake is focusing on wearable devices before defining the scientific objectives of the study. While advanced technology is important, it does not guarantee that the resulting measurements will be clinically meaningful.
The strongest partners begin by understanding the research question and then selecting technologies that support those objectives. This approach ensures that digital endpoints are driven by clinical relevance rather than device features.
Assuming Traditional CRO Experience is Sufficient
Traditional clinical research organizations provide valuable operational expertise. However, digital endpoint development requires additional capabilities in wearable sensors, digital measurement science, validation, and advanced analytics.
Sponsors should evaluate whether a potential partner has demonstrated experience across these specialized areas. This expertise is essential for developing digital endpoints that are scientifically rigorous and fit for their intended use.
Delaying Partner Engagement
Waiting until protocol development is complete can limit opportunities to optimize endpoint strategy. Early collaboration allows technology selection, endpoint planning, and operational workflows to be developed together. It also helps identify potential challenges before they affect study timelines, improving both efficiency and study quality.
Overlooking Regulatory Planning
Regulatory planning should begin early rather than being treated as a final step. Digital endpoints intended for regulatory submissions require validation strategies and evidence generation throughout the development process.
Experienced partners help sponsors build this evidence from the outset, reducing the risk of gaps that could complicate future regulatory interactions.
Avoiding these common mistakes helps sponsors select partners that contribute meaningful scientific, operational, and regulatory expertise. A thoughtful evaluation process leads to stronger digital endpoint strategies and more successful clinical development programs.
Conclusion
As digital endpoints become increasingly central to patient-focused clinical research, sponsors will need partners who can combine scientific expertise, digital measurement science, and regulatory knowledge into a cohesive development strategy.
Success depends not only on adopting innovative technologies. It is also about ensuring that digital measures are rigorously validated, clinically meaningful, and supported by high-quality evidence.
VivoSense helps sponsors achieve these goals by combining expertise in wearable sensor technologies, digital biomarkers, digital endpoint development, validation, and advanced data analytics.
By supporting every stage of the development process, VivoSense enables sponsors to transform wearable-generated data into reliable evidence. It strengthens clinical trials and supports confident regulatory decision-making.
Frequently Asked Questions
Can a traditional clinical research organization develop digital endpoints?
Some traditional clinical research organizations offer digital health capabilities, but many sponsors also work with specialized organizations that focus specifically on digital measurement science, wearable sensor validation, and digital endpoint development.
Why is validation important for digital endpoints?
Validation demonstrates that a digital endpoint accurately measures the intended clinical concept and produces reliable, meaningful results. It is essential for supporting regulatory confidence and clinical decision-making.
What is the relationship between digital biomarkers and digital endpoints?
Digital biomarkers are objective measurements collected through digital technologies, while digital endpoints are clinical trial outcomes that use those validated measurements to evaluate treatment effects or disease progression.
When should sponsors engage a digital endpoint partner?
Sponsors should ideally involve a specialized partner during protocol development or even earlier during study planning. Early collaboration helps align endpoint strategy, technology selection, validation planning, and regulatory objectives.
What qualities distinguish an experienced digital endpoint partner?
Experienced partners combine expertise in wearable technologies, digital biomarkers, clinical science, validation, data analytics, biostatistics, and regulatory strategy while supporting sponsors throughout the entire endpoint development process.